Estimating the cost effectiveness of atovaquone versus intravenous pentamidine in the treatment of mild-to-moderate Pneumocystis carinii pneumonia

PharmacoEconomics

Volumn 9, Issue 6, 1996, Pages 525-534

  Zarkin, Gary A ^a   Bala, Mohan V ^a   Wood, Lisa L ^a   Bennett, Charles L ^b,e   Simpson, Kit ^c   Dohn, Michael N ^d  

^a RTI INTERNATIONAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c IL   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; COTRIMOXAZOLE; PENTAMIDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DIARRHEA; DISEASE SEVERITY; DRUG APPROVAL; DRUG COST; FOOD AND DRUG ADMINISTRATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MODEL; NAUSEA; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME; VOMITING;

EID: 0030000880     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199609060-00007     Document Type: Article

References (14)

1. Masur H. Prevention and treatment of PCP. N Engl J Med 1992; 327: 1853-60
2. Mills J. Pneumocystis carinii and Toxoplasma gondii infections in patients with AIDS. Rev Infect Dis 1986; 8: 1001-11
3. Sattler FR, Cowan R, Nielsen DM, et al. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med 1988; 109: 280-7
4. Wharton MJ, Coleman DL, Constance B, et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med 1986; 105: 37-44
5. Dohn MN, Weinberg WG, Torres RA, et al. Oral atovaquone compared to intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med 1994; 121: 174-80
6. Bennett CL, Cvitanic M, Pascal A. The costs of AIDS in Los Angeles. J Acquir Immune Defic Syndr 1991; 4: 197-203
7. Bennett CL, Pascal A, Cvitanic M, et al. Medical care costs of intravenous drug users with AIDS in Brooklyn. J Acquir Immune Defic Syndr 1992; 5: 1-6
8. Bennett CL, Oddone E, Matchar D. Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers? Clin Perform Qual Health Care 1995; 3: 156-64
9. Bennett CL, Mathews WC, Kosecoff J, et al. Results of the Consensus panel on process of care for persons with pneumocystis carinii pneumonia [abstract]. Proceedings of the Vth International Conference on AIDS. International AIDS Society. Geneva: WHO, 1987: 284A
10. Andrulis DP, Weslowski VB, Hintz E, et al. Comparisons of hospital costs for patients with AIDS and other HIV-related conditions. JAMA 1992; 267: 2482-6
11. Health Services Cost Review Commission. Discharge Data. 1991 and 1992. Baltimore (MD): Health Services Cost Review Commission, 21215
12. Simpson K. Design and assessment of cost-effectiveness studies in AIDS populations. J Acquir Immune Defic Syndr 1995; 10 Suppl. 4: S28-32
13. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation. Med Decis Making 1985; 5: 157-77
14. Fortang IS, Moore RD. Hospital admissions of HIV-infected patients from 1988 to 1992 in Maryland. J Acquir Immune Defic Syndr 1995; 8: 365-72